BioSpace News Archive

BioAtla, Inc. announced its financial results for the second quarter ended June 30, 2023, and provided highlights on its clinical programs.

Sanara MedTech Inc., a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced details for the release of its results for the quarter ended June 30, 2023.

MiMedx Group, Inc., announced operating and financial results for the second quarter 2023, which ended June 30, 2023, including net sales of $81.3 million, net income of $1.2 million and Adjusted EBITDA1 of $14.1 million.

PROCEPT BioRobotics® Corporation announced the commencement of an underwritten public offering of $125,000,000 of shares of its common stock.

Catalent, Inc. today announced that Lisa Evoli has been named Senior Vice President & Chief Human Resources Officer, effective immediately.

Psycheceutical Bioscience, Inc. today announced that its auditors RBSM LLP have completed a PCAOB audit of the company’s financial statements for the periods ending December 31, 2022 and 2021.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has appointed Carmine Stengone as an independent member to the Company’s board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics

Reglagene, Inc. received a key investment from nationally known Tech Coast Angels Orange County, allowing the firm to advance critical studies required by the U.S. Food and Drug Administration.

The Alzheimer’s Association announced it is launching the Dementia Care Navigation Roundtable to drive access and support for people newly diagnosed and living with dementia.

IRVINE, Calif.--( BUSINESS WIRE )-- Immunis, Inc., a private biotech company developing a novel cellular secretome therapy for age and disease-related immune decline, is thrilled to announce that it has received unanimous approval from the Data Safety and Monitoring Board (DSMB) to proceed enrolling the next cohort of patients for its Phase 1/2a clinical trial. The DSMB is comprised of independent experts in the fields of medicine, investigational drug safety, and ethical patient manag